key: cord-0927523-8h33mbrj
authors: Ye, Qing; Lu, Dezhao; Zhang, Ting; Mao, Jianhua; Shang, Shiqiang
title: Recent advances and clinical application in point‐of‐care testing of SARS‐CoV‐2
date: 2022-02-05
journal: J Med Virol
DOI: 10.1002/jmv.27617
sha: af886e5e8c084ceb8126b39de29c2d7eef97e0a7
doc_id: 927523
cord_uid: 8h33mbrj

The novel coronavirus 2019 (COVID‐19) caused by SARS‐CoV‐2 spread rapidly worldwide, posing a severe threat to public life and health. It is significant to realize rapid testing and timely control of epidemic situations under the condition of limited resources. However, laboratory‐based standardized nucleic acid detection methods have a long turnaround time and high cost, so it is urgent to develop convenient methods for detecting COVID‐19. This paper summarizes the point‐of‐care testing (POCT) developed for novel coronavirus from three aspects: nucleic acid extraction, nucleic acid amplification, and detection methods. This paper introduces a commercial real‐time detection system that integrates the abovementioned three steps and the matters needing attention in use. The primary purpose of this review is to provide a reference for emergency response and rapid deployment of COVID‐19 and some other emerging infectious diseases.

detection and has become an excellent supplement to RT-PCR in standard laboratories. 7 It refers to a detection method carried out at the sampling site and uses portable analytical instruments and matching reagents to obtain results quickly. Real-time detection is not only suitable for clinical laboratories but also performed by nonlaboratory personnel with simple training at the sample collection site. In addition, real-time detection requires only a few operation steps, and the results can be read intuitively. It has the advantages of accuracy, rapidity, portability, simplicity, and low cost, conducive to faster clinical decision-making and faster screening. Therefore, it is more likely to control the epidemic situation in time.

Although rapid detection has many advantages, it also brings some new problems and puzzles to the clinical laboratory at the same time. This paper introduces the technical principle of nucleic acid POCT products in novel coronavirus, the advantages and disadvantages of existing commercial integration instant detection methods, notes, and quality assurance of the POCT nucleic acid detection system for SARS-CoV-2, and the future development direction of nucleic acid POCT products.

The core of nucleic acid POCT technology integrates nucleic acid extraction, amplification, and detection and automatically completes detection and result analysis. 8 

The extraction of nucleic acids is an extremely critical step in nucleic acid molecular detection ( Figure 1 ). To realize on-the-spot rapid detection, simplified nucleic acid extraction, also known as nucleic acid extractionfree technology, is generally adopted in COVID-19's real-time nucleic acid detection products. The simplified nucleic acid extraction process is more straightforward than the classical kit method and fully automated nucleic acid extraction technology. The steps are faster, and no additional instruments or equipment are needed. Direct lysis based on high temperature and solution is the most commonly used method to simplify the process of nucleic acid extraction. The direct method based on high temperature can release nucleic acids in a few minutes. It is a common physical lysis method that destroys the capsid of the virus using a metal bath or boiling water and then roughly extracts DNA in a short time. Its obvious advantages are simple processing, simple instrumentation, and easy operation. More specifically, only a common heating device is needed to extract nucleic acids quickly. Analogously, the solution-based direct lysis method destroys pathogens and releases RNA by adding efficient lysis buffer into samples. Another effective nucleic acid extraction method is a one-step method based on solution lysis combined with high temperature. 9 The one-step method is more straightforward than the multistep method, which reduces the possibility of opening the lid. 10 Its advantages are no complicated sample processing and nucleic acid extraction process, significantly shortened detection period, and simple operation. In addition, like Biousta, there are also classical methods of nucleic acid extraction by magnetic beads and nucleic acid amplification, realizing the rapid detection of POCT nucleic acids with "samples in and results out." 2.2 | Nucleic acid amplification (Figure 2) 2.2.1 | Reverse transcription-polymerase chain reaction (RT-PCR) RT-PCR is the most common method to detect COVID-19 nucleic acid, and the number of kits developed using this principle is also the largest. 11 The principle of RT-PCR is that reverse transcriptase is used to convert RNA into its complementary cDNA, the specific region of the cDNA is amplified by polymerase chain reaction (PCR), chemiluminescent substances are added into the system for amplification, and the fluorescence signals are read in the processor at the endpoint to realize detection. The main obstacles of applying laboratory-based RT-PCR in real-time detection include the following: real-time fluorescence detectors are usually bulky and complicated to operate, professionals are required, and the turnaround time is extended. These limitations in real-time detection prompt researchers to explore ways to simplify and shorten the process while maintaining the sensitivity and specificity of conventional RT-PCR. 12 In the sample amplification stage of RT-PCR, a thermal cycler is needed to realize the program temperature change. Nevertheless, the cost of the thermal cycler is high, so it is difficult to equip it in large quantities in areas where resources are scarce.

Isothermal amplification can rapidly amplify nucleic acids at a constant temperature without a thermal cycling step. It is the most promising alternative method of RT-PCR, which can detect viral RNA at a level similar to RT-PCR and is more suitable for real-time detection. At present, the commonly used isothermal amplification technologies for real-time detection include loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), and nicking enzyme-assisted reaction (NEAR). 13 Reverse transcription loop-mediated isothermal amplification (RT-LAMP)

RT-LAMP first reverse transcribes the RNA genome of SARS-CoV-2 into cDNA, then designs four specially designed primers that can bind to six different regions of the target genome, and uses DNA polymerase with strand displacement activity instead of thermal denaturation to generate a single-stranded template. There were two internal primers and two external primers in the four-primer system. terminal loop acts as the start of the LAMP amplification cycle so that the target sequence is exponentially amplified. LAMP has high specificity and sensitivity and is easy to perform. It can be finished in less than 1 h at a constant temperature of 60−65°C, avoiding using a thermal cycler. The assay has a high specificity, sensitivity, and robust reproducibility. Its results can be monitored using a real-time PCR machine or visualized via a colorimetric change from red to yellow.

The assay's limit of detection (LOD) is 118.6 copies of SARS-CoV-2 RNA per 25 μl reaction. 14 The reaction can be completed within 30 min for real-time fluorescence monitoring or 40 min for visual detection when the template input is more than 200 copies per 25 μl reaction. 14 However, because LAMP needs to be amplified at 60−65°C, it still needs external equipment such as a water bath and hot plate to provide constant temperature, which is not conducive to miniaturization and portability of the equipment. Therefore, it is more promising to develop isothermal amplification methods at room temperature in the future.

RPA is also an isothermal amplification method of nucleic acids. Compared with LAMP, the reaction temperature RPA is lower, and the whole reaction can be realized at normal temperature without external heating components. RPA mainly depends on three enzymes: recombinase, which can bind single-stranded nucleic acids, single-stranded DNA binding protein (SSB), and strand displacement DNA polymerase. The protein−DNA complex formed by recombinant enzymes and primers targets the homologous sequence in template DNA. A strand displacement reaction occurs through strand displacement DNA polymerase, DNA synthesis is started, and the target region on the template is exponentially amplified. The substituted DNA single-strand binds to SSB to prevent further substitution from stabilizing the open duplex structure.

Real-time fluorescence quantification was performed by combining the Exo probe. Furthermore, it can also be combined with an info probe to use lateral flow test strips to detect or add dye to visually detect and read, which will be more suitable for real-time detection. The single-tube RT-RPA method based on the Exo probe is 100% consistent with RT-qPCR. 15 The detection limit can reach 7.74 copies per reaction. The results can be obtained within 7 min at the earliest, which is one of the fastest nucleic acid-based detection methods for SARS-CoV-2 thus far. 16 RPA has high sensitivity and can be amplified at room temperature without heating parts, and the reaction speed is faster than that of LAMP.

However, the application of this method in real-time detection is limited by patent protection.

NEAR is driven by reverse transcriptase, nicking enzymes, and isothermal amplification DNA polymerase. The template hybridizes with the primer, the extension product is replaced by the next template, the complementary strand of the replacement product is extended to form the nicking enzyme recognition site, and the nicking enzyme recognizes and cuts the specific short sequence of one strand in the double-stranded DNA to form a gap. Constant temperature-amplified DNA polymerase extends nucleotides from the 3' end of primers to synthesize short sequences, thus obtaining double-stranded NEAR amplification. The target DNA template is continuously amplified through cutting and extension cycles, and the molecular beacon is designed to generate fluorescent signals for quantification. 17 NEAR is amplified exponentially, so this method has a high reaction speed and sensitivity. The disadvantage is that the design of short sequences increases the false positive rate. 

Paper-based lateral flow analysis (LFA) is a potential tool for home detection or detection in resource-poor areas because of its low cost, easy manufacture, and full compatibility with real-time detection. The most common method is a colorimetric determination by color change caused by the aggregation of AuNPs. 18 At present, the Accula (MesaBiotech) company has developed commercial instruments using lateral flow technology as the detection method.

Compared with fluorescence detection, which requires special instruments to read signals, visual detection can be observed by the naked eye, making it more straightforward and intuitive to read the results and more suitable for real-time detection. Visualization includes colorimetry with pH-sensitive dyes, turbidity methods, or fluorescent dye methods. Visualization is often used in isothermal amplification, which can further adapt to the use scene of real-time detection, reduce the professional requirements of operators, and do not need special equipment. However, when compared with fluorescence detection, the sensitivity of visual inspection decreases.

Combining smartphone imaging and sensing platforms can realize the quantification of visual results, which is more objective than visual judgment and can improve detection accuracy. 19 

The CRISPR/Cas system is a common tool for gene editing that can accurately identify and cut specific sequences. In contrast, the activated Cas enzyme can precisely cut target RNA and nonspecifically cut RNA or DNA in the surrounding environments, which can be used to detect a nucleic acid. 

Cas12, another member of the CRISPR/Cas effector family, has the characteristic of target-activated nonspecific single-stranded deoxyribonuclease (ssDNase) and is an RNA-guided DNA endonuclease. 22 Viral RNA is first transformed into DNA, and then the specific target sequence in isothermal amplified DNA activates Cas12a. Next, Cas12a sequentially cuts the ssDNA reporter probe to release macroscopic fluorescent molecules. 22 This method can realize sensitive and specific DNA detection and can easily realize high throughput and automation. Meanwhile, the detection limit is two copies per reaction, and the sensitivity is better than QCPR. 23 However, there is still a lack of related real-time detection equipment. Of course, CRISPR can also use lateral flow test strips to detect signals, but the detection sensitivity will be reduced. 24 An RNA-based CRISPR/Cas strategy combined with isothermal amplification can improve the sensitivity, specificity, and reliability of isothermal amplification.

CRISPR detection can also be coupled with lateral flow reading, which is quite suitable for home detection, showing broad prospects for developing next-generation molecular diagnostic technology and the application of real-time detection. CoV-2 was low, with a specific value of only 8.26 copies/ml. 27, 28 Many studies have demonstrated that Visby COVID-19 meets the requirements of rapid testing of SARS-CoV-2 and has a high concordance with central laboratory-based RT-qPCR methods. When detecting SARS-CoV-2 RNA, the sensitivity and specificity of RT-PCR POC technology are 95% and 100%, respectively. 29 The detection limit was as low as or lower YE ET AL. | 1871 than 500 copies/ml. 30 RT-PCR molecular diagnosis technology was combined with LFA technology in the Accula of Mesa Biotech company.

The instruments used in this detection process are compact and easy to operate. It takes only half an hour to complete the detection and obtain the results. One hundred nasopharyngeal swab samples were detected in a clinical study, the results of which showed that the overall consistency and the positive consistency with RT-PCR were 84% and 68%, respectively. Low viral load samples are more likely to have false negatives. 31 The above conclusion shows that the sensitivity of the Accula of Mesa Biotech company is not as high as we expected. Studies are evaluating the concordance between laboratory-developed RT-PCR detection and Roche Diagnostics Cobas 6800 SARS-CoV-2 detection. The results

showed that the overall percent agreement was up to 95.8%, and Cohen's κ coefficient was 0.904 between the two platforms mentioned above. 32 Abbott's ID designs directional amplification of the RdRp fragment of SARS-CoV-2 based on the NEAR principle, and now it has been widely used for commercial real-time detection. It takes only 5−13 min for this product to detect, but the positive coincidence rate between RT-PCR and ID NOW is approximately 80%, which is consistent with previous studies. These findings suggest that Abbott's ID may not be appropriate to detect weakly positive samples. [33] [34] [35] [36] [37] [38] [39] [40] [41] In addition, there are commercial platforms that can realize multiplex PCR, including QIAstat-Dx of QIAGEN company and Bio-Fire FilmArray of bioMérieux company. In addition to supporting liquid transport media, QI-STAT-DX also has a unique dry swab direct loading procedure, which can obtain results within 1 h, and the manual operation takes less than 1 min. BioFire FilmArray uses nested multiplex PCR combined with microfluidic chip technology to realize 1-h rapid detection. Nested PCR technology can eliminate the interference of other nonspecific pathogen nucleic acid substances to the greatest extent and improve the detection sensitivity. 31 Isothermal amplification integrated instruments are suitable for portable rapid detection in resource-deficient areas and crowded environments. At present, an isothermal nucleic acid amplification instrument suitable for real-time detection is urgently needed. Several assays use isothermal nucleic acid amplification technology for the qualitative detection of SARS-CoV-2 viral nucleic acids, including the Cue COVID-19

Test, Detect Covid-19 Test, and Talis One COVID-19 Test System. detection method uses real-time isothermal amplification technology, and aTalis One instrument is used when the extracted nucleic acid is amplified and detected. However, clinical validation data for the Talis One COVID-19 Test System and the Detect COVID-19 Test are lacking because these two detection methods have just completed development.

Some convalescent homes in the United Kingdom have recently tried a new model called POCKITTM Central. It is a benchtop molecular detection system that integrates insulated isothermal PCR amplification/ detection based on fluorescence, magnetic bead-based nucleic acid extraction, and liquid handling technologies. It offers a straightforward protocol for nucleic acid detection. When RT-PCR is used as the reference standard, POCKITTM Central has acceptable sensitivity and specificity, especially for cases with symptoms. To be more specific, eight specimens can be detected at once, and the results are displayed on the monitor no more than one and a half an hour. 43 

China has also made outstanding contributions to the research and development of POCT nucleic acid detection systems for SARS-CoV-2. The laboratory should use the highly sensitive (detection limit ≤500 copies/ml) detection reagent approved by the National Medical Products Administration. The rapid detection reagent manufacturer must provide the analytical performance of the whole rapid detection system, including but not limited to the detection limit and precision. The laboratory should establish standard operating procedures for the entire process of detection operation according to the reagent instructions.

Before conducting clinical tests, the laboratory should verify the performance of the whole rapid detection system. For performance verification, pseudovirus positive quality control products and negative clinical specimens packed with corresponding virus RNA sequences with known concentrations can be used. Performance indicators include but are not limited to detection limit and precision. If the laboratory is equipped with multiple rapid detection instruments, the laboratory should evaluate the reproducibility of different instruments.

The laboratory should carry out indoor quality control. Indoor quality control products should include negative quality control products (normal saline) and weak positive quality control products whose concentration is 1.5−3 times the detection limit. Every time you turn on the machine, first detect weak positive quality control products and negative quality control products. After quality control was qualified, clinical specimen detection started. In addition, it is necessary to participate in ventricular interstitial assessment regularly.

The laboratory should analyze and explain the results according to the reagent instructions. Comprehensive judgment should be made in combination with the original amplification curve for fast detection equipment that can automatically report the results and display the original amplification curve. When the detection limit of the rapid detection system is ≤500 copies/ml, the detection result is negative, and the negative result can be directly reported. The test result is positive. The original sample should be rechecked with another 1−2 kinds of conventional nucleic acid detection reagents that are more sensitive, preferably for amplifying different target areas. If necessary, the patient can be resampled for re-examination, and the results can only be reported if the re-examination is positive.

Although the rapid detection platform integrating nucleic acid extraction and amplification detection is simple to operate, the whole experimental process still involves many aspects, such as "anticontamination" nucleic acid detection, performance verification, equipment maintenance, indoor quality control, result analysis and reporting, laboratory biosafety, and so forth. Nucleic acid rapid detection laboratory personnel still need to go through the on-the-job training of the clinical gene amplification detection laboratory, obtain corresponding qualifications, and can only go on the job after the basic training of 2019-nCoV nucleic acid rapid detection and the evaluation of working ability. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The case for improved diagnostic tools to control Ebola virus disease in West Africa and how to get there

The WHO clinical case definition for suspected cases of Ebola virus disease arriving at Ebola holding units: reason to worry?

Be alert to superposed effect of seasonal influenza while fighting against novel coronavirus pneumonia

Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM)-does it leverage any advantage in clinical decision making?

Current and future point-of-care tests for emerging and new respiratory viruses and future perspectives

Point-of-care testing (POCT): current techniques and future perspectives

The FilmArray ® respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens

A rapid and sensitive recombinase aided amplification assay to detect hepatitis B virus without DNA extraction

Loop-mediated isothermal amplification assay for rapid detection of Streptococcus agalactiae (group B streptococcus) in vaginal swabs-a proof of concept study

Point-of-care testing detection methods for COVID-19

Evaluation of a new point-ofcare quantitative reverse transcription polymerase chain test for detecting severe acute respiratory syndrome coronavirus 2

Loop-mediated isothermal amplification (LAMP): a rapid, sensitive, specific, and cost-effective point-of-care test for coronaviruses in the context of COVID-19 pandemic

A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2

Single-copy sensitive, field-deployable, and simultaneous dual-gene detection of SARS-CoV-2 RNA via modified RT-RPA

Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an Exo probe with an internally linked quencher (Exo-IQ)

Isothermal reactions for the amplification of oligonucleotides

Selective nakedeye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles

Rapid isothermal amplification and portable detection system for SARS-CoV-2

Nucleic acid detection with CRISPR-Cas13a/C2c2

Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity

Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis

CRISPR-Cas12-based detection of SARS-CoV-2

Spike mutation D614G alters SARS-CoV-2 fitness

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

Detection of SARS-CoV-2 by use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays

Multi-center evaluation of cepheid xpert ® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic

Analytical evaluation of Visby medical RT-PCR portable device for rapid detection of SARS-CoV-2

Evaluation of the Visby medical COVID-19 point of care nucleic acid amplification test

Comparison of the Accula SARS-CoV-2 test with a laboratory-developed assay for detection of SARS-CoV-2 RNA in clinical nasopharyngeal specimens

Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test

Diagnostic performance of a rapid point-of-care test for SARS-CoV-2 in an urban emergency department setting

Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York city academic institution

A comparison of five SARS-CoV-2 molecular assays with clinical correlations

Comparative study of four SARS-CoV-2 nucleic acid amplification test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type

Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19

Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens

How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory

Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency department

Evaluation of the COVID19 ID NOW EUA assay

Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection center

Is point-of-care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of a point-of-care polymerase chain reaction test for SARS-CoV-2

Recent advances and clinical application in point-of-care testing of SARS-CoV-2

The authors declare that there are no conflict of interests.

Shiqiang Shang and Jianhua Mao had the idea for and designed the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Qing Ye contributed to the writing of the report. Qing Ye, Shiqiang Shang, Dezhao Lu, Ting Zhang, and Jianhua Mao contributed to the critical revision of the report. All authors contributed to data acquisition, analysis, or interpretation and reviewed and approved the final version.

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

https://orcid.org/0000-0002-6756-0630